A Phase 1 interventional study of GC3114 and GCFLU Quadrivalent in Influenza, Human, sponsored by Green Cross Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-19.
Sponsored by Green Cross Corporation · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Influenza, Human by GC Biopharma Corp. — 1 open to participants now, 1 under way, 1 of them phase 3. Influenza, Human · GC Biopharma Corp..
Among the 16 studies in Influenza, Human by GC Biopharma Corp., this one is the 16th largest by enrollment, is one of 2 that started in 2017, is the only one in phase 1, and was the 14th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →1 of the 16 studies in Influenza, Human by GC Biopharma Corp. is open now, in 1 country. Recruiting first, the newest first:
GC Biopharma Corp · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 19 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 10 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 40 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 407 across the 16 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Green Cross Corporation, one of the names counted as GC Biopharma Corp.. Under that name alone:
Green Cross Corporation is the lead sponsor of 63 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Influenza, Human by GC Biopharma Corp., from their registry updates:
This tab as a report to print or save as PDF → With an account.
Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..
Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj.. Safety and immunological efficacy will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pre-filled syringe inj., 0.5ml, Once, IM
Biological: GC3114
Pre-filled syringe inj., 0.5ml, Once, IM
Biological: GCFLU Quadrivalent
High-dose Quadrivalent influenza vaccine
Quadrivalent influenza vaccine
Adverse Event
Solicited/Unsolicited Adverse Event
Time frame: for 7 days from Day0/during study period
Percentage of participants achieving pre-defined Seroconversion Before and following vaccination
Seroconversion rate (SCR)
Time frame: Day 0 and Day 21
Percentage of participants achieving pre-defined Seroprotection Before and following vaccination
Seroprotection rate (SPR)
Time frame: Day 0 and Day 21
Geometric Mean Titer and Geometric Mean Titer Ratios of Antibodies to the Investigational Product Before and Following vaccination
Geometric Mean Titer(GMT), Geometric Mean Titer(GMT)
Time frame: Day 0 and Day 21
Plan to share: No
Ran from Nov 2017 to primary completion in Dec 2017, 1 month.
Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.